Sol-Gel Technologies (NASDAQ: SLGL) is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our unique technology platform was designed to enable drug substances to be entrapped in porous silica microcapsules in order to address the limitations of topical drug delivery by stabilizing active drug ingredients, extending drug delivery time and reducing potential irritation caused by direct application to the skin. For more information, please visit www.Sol-Gel.com